Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase I Studies in Hematologic Malignancy: 20-Year Experience from Cancer Therapy Evaluation Program (CTEP) at National Cancer Institute/National Institutes of Health

Dai Chihara, MDPhD, Erich P. Huang, PhD, Shanda R. Finnigan, MPH, RN, Lisa M. Cordes, PharmD, Nebojsa Skorupan, MD, Yoko Korenaga Fukuda, MD, Larry V. Rubinstein, PhD, Naoko Takebe, MD PhD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-140159

Published: 2020

Journal Articles

Obatoclax in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL

Jennifer R Brown, MD, PhD, Bethany Tesar, Lillian Werner, Evgeny Mikler, Hazel Reynolds, Christina Thompson, David C. Fisher, MD, Naoko Takebe, MD, PhD, Donna Neuberg, ScD, Arnold S. Freedman, MD

Blood (2011) 118 (21): 2865.

https://doi.org/10.1182/blood.V118.21.2865.2865

Published: 2011

Journal Articles

Attenuation of Surface CXCR4 Down-Regulation in Human Cord Blood HSC during Ex Vivo Expansion Using the HUBEC Co-Culture System.

Naoko Takebe, MD, PhD, Thomas MacVittie, PhD, Xiangfei Cheng, MD, PhD, Ann M. Farese, MS, Emily Welty, MS, Barry Meisenberg, MD

Blood (2005) 106 (11): 1068.

https://doi.org/10.1182/blood.V106.11.1068.1068

Published: 2005

Journal Articles

Human Brain Endothelial Cells (HUBEC) Can Expand Both Human Bone Marrow and Cord Blood SCID-Repopulating Cells (SRC) through Cell Contact Rather Than Soluble Factors.

Naoko Takebe, MD, PhD, Xiangfei Cheng, MD, PhD, Ann M. Farese, MS, Emily Welty, MS, Barry Meisenberg, MD, Thomas MacVittie, PhD

Blood (2005) 106 (11): 36.

https://doi.org/10.1182/blood.V106.11.36.36

Published: 2005

Journal Articles

Novel Retinoic Acid Metabolism Blocking Agents (RAMBAs) Induce Differentiation in ATRA Resistant Cell Line: Potential New Theraputics for Acute Promyleocytic Leukemia (APL).

Kavita B. Kalra, MD, Xiangfei Cheng, MD, PhD, Marion Womak, Christopher Gocke, MD, Jyoti B. Patel, PhD, Vincent C.O. Njar, PhD, Naoko Takebe, MD, PhD

Blood (2005) 106 (11): 746.

https://doi.org/10.1182/blood.V106.11.746.746

Published: 2005

NARROW

Phase I Studies in Hematologic Malignancy: 20-Year Experience from Cancer Therapy Evaluation Program (CTEP) at National Cancer Institute/National Institutes of Health

Obatoclax in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL

Attenuation of Surface CXCR4 Down-Regulation in Human Cord Blood HSC during Ex Vivo Expansion Using the HUBEC Co-Culture System.

Human Brain Endothelial Cells (HUBEC) Can Expand Both Human Bone Marrow and Cord Blood SCID-Repopulating Cells (SRC) through Cell Contact Rather Than Soluble Factors.

Novel Retinoic Acid Metabolism Blocking Agents (RAMBAs) Induce Differentiation in ATRA Resistant Cell Line: Potential New Theraputics for Acute Promyleocytic Leukemia (APL).

Email alerts

ASH Publications

American Society of Hematology

Phase I Studies in Hematologic Malignancy: 20-Year Experience from Cancer Therapy Evaluation Program (CTEP) at National Cancer Institute/National Institutes of Health

Obatoclax in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL

Attenuation of Surface CXCR4 Down-Regulation in Human Cord Blood HSC during Ex Vivo Expansion Using the HUBEC Co-Culture System.

Human Brain Endothelial Cells (HUBEC) Can Expand Both Human Bone Marrow and Cord Blood SCID-Repopulating Cells (SRC) through Cell Contact Rather Than Soluble Factors.

Novel Retinoic Acid Metabolism Blocking Agents (RAMBAs) Induce Differentiation in ATRA Resistant Cell Line: Potential New Theraputics for Acute Promyleocytic Leukemia (APL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only